Citations

Clear

4093 citation(s) found for "Yu, Jonathan".

Behavioral economics—A framework for donor organ decision‐making in pediatric heart transplantation
Butler, Alison , Chapman, Gretchen B. , Johnson, Jonathan N. , Amodeo, Antonio , Böhmer, Jens , Camino, Manuela , Davies, Ryan R. , Dipchand, Anne I. , Miera, Oliver , Pérez‐Blanco, Alicia , Rosenthal, David N. , Zangwill, Steve, Kirk, Richard , Chapman, Gretchen , Zangwill, Steve , Godown, Justin A. , Zangwill, Steven

Mayo Clinic

Pediatric Transplantation | January 27, 2020 | Volume: 24 | Issue: 3 | Pages: No page available

10.1111/petr.13655 | PMID 31985140 Get It

AbstractThe high discard rate of pediatric donor hearts presents a major challenge for children awaiting heart transplantation. Recent literature identifies several factors that contribute to the disparities in pediatric donor heart usage, including regulatory oversight, the absence of guidelines on pediatric donor heart acceptance, and variation among transplant programs. However, a likely additional contributor to this issue are the behavioral factors influencing transplant team decisions in donor offer scenarios, a topic that has not yet been studied in detail. Behavioral economics and decision psychology provide an excellent foundation for investigating decision‐making in the pediatric transplant setting, offering key insights into the behavior of transplant professionals. We conducted a systematic review of published literature in pediatric heart transplant related to behavioral economics and the psychology of decision‐making. In this review, we draw on paradigms from these two domains in order to examine how existing aspects of the transplant environment, including regulatory oversight, programmatic variation, and allocation systems, may precipitate potential biases surrounding donor offer decisions. Recognizing how human decision behavior influences donor acceptance is a first step toward improving utilization of potentially viable pediatric donor hearts.
Diversity and inclusion in pain medicine
Hagedorn, Jonathan M. , Moeschler, Susan M. , Goree, Johnathan , Weisbein, Jackie, Moeschler, Susan, Hagedorn, Jonathan M , Weisbein, Jacqueline S. , Deer, Timothy R.

Mayo Clinic

Regional Anesthesia & Pain Medicine | January 22, 2020 | Volume: 45 | Issue: 10 | Pages: 839-839

10.1136/rapm-2020-101284 | PMID 31969441 Get It

Marijuana in pediatric and adult congenital heart disease heart transplant listing: A survey of provider practices and attitudes
Phillips, Kari A. , Thrush, Philip T. , Lal, Ashwin K. , Kindel, Steven J. , Castleberry, Chesney , Sparks, Joshua D. , Johnson, Jonathan N. , Sparks, Joshua , Daly, Kevin P , Johnson, Jonathan

Mayo Clinic

Pediatric Transplantation | January 21, 2020 | Volume: 24 | Issue: 2 | Pages: No page available

10.1111/petr.13640 | PMID 31960528 Get It

Abstract Despite increasing legalization and use of marijuana, there is no consensus among pediatric heart transplant institutions or providers regarding users' eligibility for cardiac transplant. We sent a survey to pediatric and ACHD transplant providers (physicians, surgeons, transplant coordinators, and pharmacists) assessing their current institution's policies and their personal opinions about marijuana use in patients being considered for heart transplantation. Of the respondents, 84% practice in the United States and Canada. Most providers (80%) care for both pediatric and ACHD patients. Respondents included cardiologists (77%) and surgeons (11%), with the remaining being coordinators and pharmacists. Most providers (73%) reported their institution had no policy regarding marijuana use in heart transplant candidates. Only 20% of respondents' institutions consider mode of consumption, with 87% and 53% approving of oral and transdermal routes, respectively, and only 7% approving of vaporized or smoked routes. While 73% of providers would consider illegal marijuana use an absolute/relative contraindication to heart transplant listing, the number decreases to 57% for legal recreational users and 21% for legal medical users. Most providers personally believe marijuana to be physically and mentally/emotionally harmful to pediatric patients (67% and 72%, respectively). Many institutions lack a policy regarding marijuana use in pediatric and ACHD heart transplant candidates, and there is considerable disagreement among providers on the best practice. With increasing legalization and use of marijuana, each institution will have to address this issue thoughtfully to continue to provide high‐quality, consistent, and equitable care for pediatric and ACHD heart transplant candidates.
Orthobiologics for the Hip Region: A Narrative Review
McInnis, Kelly C. , Chen, Eric T. , Finnoff, Jonathan T. , Roh, Eugene Y. , Stein, Joanne Borg, Finnoff, Jonathan T , Chen, Eric T.

Mayo Clinic

PM&R | January 18, 2020 | Volume: 12 | Issue: 10 | Pages: 1045-1054

10.1002/pmrj.12327 | PMID 31953917 Get It

Management of hip region disorders is challenging. Orthobiologic treatments including platelet rich plasma (PRP), mesenchymal stem cells, and amniotic injectables have gained popularity as promising treatments despite a lack of robust evidence for their effectiveness. We review rationale and current evidence for orthobiologics for three common hip region conditions: hip osteoarthritis, gluteal tendinopathy, and proximal hamstring tendinopathy. Overall, the current state of evidence is extremely limited for orthobiologic treatments and is predominantly relevant to PRP injections. There is currently a lack of data to support the use of mesenchymal stem cells or amniotic injectables in these conditions of the hip.
Comparison of sporadic and familial behavioral variant frontotemporal dementia (FTD) in a North American cohort
Heuer, Hilary W. , Wang, P., Rascovsky, Katya, Bove, Jessica, Bordelon, Yvette , Brannelly, Patrick , Brushaber, Danielle , Caso, Christine, Coppola, Giovanni , Dickerson, Brad C., Dickinson, Susan, Domoto‐Reilly, Kimiko , Faber, Kelley , Ferrall, Jessica, Fields, Julie A. , Fishman, Ann, Forsberg, Leah K. , Gearhart, Debra, Ghazanfari, Behnaz, Ghoshal, Nupur , Graff‐Radford, Jonathan , Graff-Radford, N. R., Grant, Ian , Haley, Dana , Hsiung, Ging‐Yuek Robin , Huey, Edward D. , Irwin, David J. , Kantarci, Kejal , Karydas, Anna, Kaufer, Daniel , Kornak, John , Kramer, Joel H. , Kraft, Ruth, Kremers, Walter K. , Kukull, Walter A. , Ljubenkov, Peter A. , Mackenzie, Ian R. , Maldonado, Miranda, Manoochehri, Masood , McGinnis, Scott, McKinley, Emily , Mendez, Mario F. , Miller, Bruce L. , Onyike, Chiadi U. , Pantelyat, Alexander , Pearlman, Rodney , Petrucelli, Leonard , Rademakers, Rosa , Ramos, Eliana Marisa , Rankin, Katherine P. , Roberson, Erik D. , Rogalskı, Emily , Sengdy, Pheth, Shaw, Leslie M. , Syrjanen, Jeremy A. , Tartaglia, Maria Carmela , Tatton, Nadine , Taylor, Joanne, Trojanowski, John Q. , Weıntraub, Sandra , Wong, Bonnie , Rosen, Howard J. , Boxer, Adam L. , consortia, on behalf of the ARTFL and LEFFTDS, Irwin, David J , Hsiung, Gink-Yuek , Roberson, Erik , Miller, Bruce L , Kantarci, Kejal , Pantelyat, Alex , Tartaglia, Maria Carmela , Kremers, Walter K , Domoto-Reilly, Kimiko , Wolf, A., Appleby, Brian S. , Fong, Jamie , Foroud, Tatiana , Goldman, Jill , Grossman, Murray , Jones, David T. , Kerwin, Diana , Knopman, David S. , Litvan, Irene , Potter, M., Toga, Arthur W. , Wszołek, Zbigniew K. , Boeve, Bradley F. , consortia, on behalf of the ARTFL and LEFFTDS

Mayo Clinic

Alzheimer's & Dementia | January 16, 2020 | Volume: 16 | Issue: 1 | Pages: 60-70

10.1002/alz.12046 | PMID 31914226 Get It

AbstractIntroductionBehavioral variant frontotemporal dementia (bvFTD) may present sporadically or due to an autosomal dominant mutation. Characterization of both forms will improve understanding of the generalizability of assessments and treatments.MethodsA total of 135 sporadic (s‐bvFTD; mean age 63.3 years; 34% female) and 99 familial (f‐bvFTD; mean age 59.9; 48% female) bvFTD participants were identified. f‐bvFTD cases included 43 with known or presumed chromosome 9 open reading frame 72 (C9orf72) gene expansions, 28 with known or presumed microtubule‐associated protein tau (MAPT) mutations, 14 with known progranulin (GRN) mutations, and 14 with a strong family history of FTD but no identified mutation.ResultsParticipants with f‐bvFTD were younger and had earlier age at onset. s‐bvFTD had higher total Neuropsychiatric Inventory Questionnaire (NPI‐Q) scores due to more frequent endorsement of depression and irritability.Discussionf‐bvFTD and s‐bvFTD cases are clinically similar, suggesting the generalizability of novel biomarkers, therapies, and clinical tools developed in either form to the other.
Utility of the global CDR® plus NACC FTLD rating and development of scoring rules: Data from the ARTFL/LEFFTDS Consortium
Miyagawa, Toji , Brushaber, Danielle , Syrjanen, Jeremy A. , Kremers, Walter K. , Fields, Julie A. , Forsberg, Leah K. , Heuer, Hilary W. , Kornak, John , Boxer, Adam L. , Rosen, Howard J. , Bordelon, Yvette , Bove, Jessica, Brannelly, Patrick , Caso, Christina, Coppola, Giovanni , Dever, Reilly, Dheel, Christina, Dickinson, Susan, Domínguez, S. Carbajal, Domoto‐Reilly, Kimiko , Faber, Kelley , Ferrell, Jessica, Fishman, Ann, Gavrilova, Ralitza H. , Gearhart, Debra, Ghazanfari, Behnaz, Ghoshal, Nupur , Graff‐Radford, Jonathan , Graff‐Radford, Neill R. , Grant, Ian , Haley, Dana , Hsiung, Ging‐Yuek Robin , Huey, Edward D. , Irwin, David J. , Jones, Lynne C. , Kantarci, Kejal , Karydas, Anna, Kaufer, Daniel , Kraft, Ruth, Kramer, Joel H. , Kukull, Walter A. , Lucente, Diane , Lungu, Codrin , Mackenzie, Ian R. , Maldonado, Miranda, Manoochehri, Masood , McGinnis, Scott, McKinley, Emily , Mendez, Mario F. , Miller, Bruce L. , Multani, Namita, Onyike, Chiadi U. , Padmanabhan, Jaya , Pantelyat, Alexander , Pearlman, Rodney , Petrucelli, Leonard , Potter, Madeline, Rademakers, Rosa , Ramos, Eliana Marisa , Rankin, Kate, Rascovsky, Katya, Roberson, Erik D. , Rogalskı, Emily , Sengdy, Pheth, Shaw, Leslie M. , Tartaglia, Maria Carmela , Tatton, Nadine , Taylor, Joanne, Toga, Arthur W. , Trojanowski, John Q. , Wang, Ping , Weıntraub, Sandra , Wong, Bonnie , Irwin, David J , Hsiung, Gink-Yuek , Roberson, Erik , Miller, Bruce L , Kantarci, Kejal , Pantelyat, Alex , Tartaglia, Maria Carmela , Kremers, Walter K , Domoto-Reilly, Kimiko , Knopman, David S. , Boeve, Bradley F. , Appleby, Brian S. , Dickerson, Bradford Clark , Fong, Jamie , Foroud, Tatiana , Goldman, Jill , Grossman, Murray , Jones, David T. , Jones, Lynne, Kerwin, Diana , Litvan, Irene , Wszołek, Zbigniew K.

Mayo Clinic

Alzheimer's & Dementia | January 16, 2020 | Volume: 16 | Issue: 1 | Pages: 106-117

10.1002/alz.12033 | PMID 31914218 Get It

AbstractIntroductionWe created global rating scoring rules for the CDR® plus NACC FTLD to detect and track early frontotemporal lobar degeneration (FTLD) and to conduct clinical trials in FTLD.MethodsThe CDR plus NACC FTLD rating was applied to 970 sporadic and familial participants from the baseline visit of Advancing Research and Treatment in Frontotemporal Lobar Degeneration (ARTFL)/Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects (LEFFTDS). Each of the eight domains of the CDR plus NACC FTLD was equally weighed in determining the global score. An interrater reliability study was completed for 40 participants.ResultsThe CDR plus NACC FTLD showed very good interrater reliability. It was especially useful in detecting clinical features of mild non‐fluent/agrammatic variant primary progressive aphasia participants.DiscussionThe global CDR plus NACC FTLD score could be an attractive outcome measure for clinical trials in symptomatic FTLD, and may be useful in natural history studies and clinical trials in FTLD spectrum disorders.
Genetic screening of a large series of North American sporadic and familial frontotemporal dementia cases
Ramos, Eliana Marisa , Dokuru, Deepika , Berlo, Victoria Van, Wojta, Kevin , Huang, Alden , Deverasetty, Sandeep, Qin, Yue , Blitterswijk, Marka van , Jackson, Jazmyne L. , Bordelon, Yvette , Brannelly, Patrick , Brushaber, Danielle , Dickinson, Susan, Domoto‐Reilly, Kimiko , Faber, Kelley , Fields, Julie A. , Forsberg, Leah K. , Gavrilova, Ralitza H. , Ghoshal, Nupur , Graff‐Radford, Jonathan , Graff‐Radford, Neill R. , Grant, Ian , Heuer, Hilary W. , Hsiung, Ging‐Yuek Robin , Huey, Edward D. , Irwin, David J. , Kantarci, Kejal , Karydas, Anna, Kaufer, Daniel , Kornak, John , Kramer, Joel H. , Kremers, Walter K. , Kukull, Walter A. , Ljubenkov, Peter A. , Lungu, Codrin , Mackenzie, Ian R. , Mendez, Mario F. , Miller, Bruce L. , Onyike, Chiadi U. , Pantelyat, Alexander , Pearlman, Rodney , Petrucelli, Len, Potter, Madeline, Rankin, Katherine P. , Rascovsky, Katya, Roberson, Erik D. , Rogalskı, Emily , Shaw, Leslie M. , Syrjanen, Jeremy A. , Tartaglia, Maria Carmela , Tatton, Nadine , Taylor, Joanne, Trojanowski, John Q. , Weıntraub, Sandra , Wong, Bonnie , Rademakers, Rosa , Rosen, Howard J. , Boxer, Adam L. , Coppola, Giovanni, Jackson, Jazmyne, Brushaber, Danielle E, Boeve, Brad F, van Blitterswijk, Marka , Irwin, David J , Hsiung, Gink-Yuek , Roberson, Erik , Miller, Bruce L , Kantarci, Kejal , Pantelyat, Alex , Tartaglia, Maria Carmela , Kremers, Walter K , Domoto-Reilly, Kimiko , Wang, Qing , Appleby, Brian S. , Dickerson, Bradford Clark , Fong, Jamie , Foroud, Tatiana , Goldman, Jill , Grossman, Murray , Kerwin, Diana , Knopman, David S. , Litvan, Irene , Toga, Arthur W. , Wszołek, Zbigniew K. , Boeve, Bradley F. , Coppola, Giovanni

Mayo Clinic

Alzheimer's & Dementia | January 16, 2020 | Volume: 16 | Issue: 1 | Pages: 118-130

10.1002/alz.12011 | PMID 31914217 Get It

AbstractIntroductionThe Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) and Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects (LEFFTDS) consortia are two closely connected studies, involving multiple North American centers that evaluate both sporadic and familial frontotemporal dementia (FTD) participants and study longitudinal changes.MethodsWe screened the major dementia‐associated genes in 302 sporadic and 390 familial (symptomatic or at‐risk) participants enrolled in these studies.ResultsAmong the sporadic patients, 16 (5.3%) carried chromosome 9 open reading frame 72 (C9orf72), microtubule‐associated protein tau (MAPT), and progranulin (GRN) pathogenic variants, whereas in the familial series we identified 207 carriers from 146 families. Of interest, one patient was found to carry a homozygous C9orf72 expansion, while another carried both a C9orf72 expansion and a GRN pathogenic variant. We also identified likely pathogenic variants in the TAR DNA binding protein (TARDBP), presenilin 1 (PSEN1), and valosin containing protein (VCP) genes, and a subset of variants of unknown significance in other rare FTD genes.DiscussionOur study reports the genetic characterization of a large FTD series and supports an unbiased sequencing screen, irrespective of clinical presentation or family history.
An International Multicenter Evaluation of Type 5 Long QT Syndrome
Roberts, Jason D. , Asaki, S. Yukiko , Mazzanti, Andrea , Bos, J. Martijn , Tuleta, Izabela , Muir, Alison , Crotti, Lia , Kutyifa, Valentina , Shoemaker, M. Benjamin , Johnsrude, Christopher L. , Aiba, Takeshi , Marcondes, Luciana, Baban, Anwar , Udupa, Sharmila, Dechert, Brynn E. , Fischbach, Peter , Knight, Linda M., Kukavica, Deni , Stallmeyer, Birgit, Giudicessi, John R. , Spazzolini, Carla , Cadrin‐Tourigny, Julia , Simpson, Christopher S. , Roston, Thomas M. , Hajjaji, Imane El , Yousif, Maisoon D. , Gula, Lorne J. , Leong‐Sit, Peter , Chavali, Nikhil, Landstrom, Andrew P. , Marcus, Gregory M. , Dittmann, Sven , Wilde, Arthur A.M. , Behr, Elijah R. , Tfelt‐Hansen, Jacob , Kaski, Juan Pablo , Gow, Robert M., Aziz, Peter F. , Abrams, Dominic J. , Skinner, Jonathan R. , Kaufman, Elizabeth S. , Roden, Dan M. , Zaręba, Wojciech , Schulze‐Bahr, Eric , Etheridge, Susan P. , Priori, Silvia G. , Ackerman, Michael J. , Crotti, Lia , Behr, Elijah Raphael , Landstrom, Andrew P , Bos, Johan M , Tfelt-Hansen, Jacob , Skinner, Jonathan R , Abrams, Dominic J , Baban, Anwar , Kaski, Juan P , Johnsrude, Christopher , Mazzanti, Andrea , Cadrin-Tourigny, Julia , Zareba, Wojciech , Spazzolini, Carla , Priori, Silvia , Marcus, Gregory M , Krahn, Andrew D. , Aiba, Takeshi , Knight, Linda M., Vittinghoff, Eric , Shimamoto, Keiko , Tadros, Rafik , Duff, Henry J. , Wijeyeratne, Yanushi D. , Scheinman, Melvin M , Pérez, Marco , Drago, Fabrizio , Gollob, Michael H. , Shimizu, Wataru , Roden, Dan M. , Schwartz, Peter J.

Mayo Clinic

Circulation | January 16, 2020 | Volume: 141 | Issue: 6 | Pages: 429-439

10.1161/circulationaha.119.043114 | PMID 31941373 Get It

Background: Insight into type 5 long QT syndrome (LQT5) has been limited to case reports and small family series. Improved understanding of the clinical phenotype and genetic features associated with rare KCNE1 variants implicated in LQT5 was sought through an international multicenter collaboration. Methods: Patients with either presumed autosomal dominant LQT5 (N = 229) or the recessive Type 2 Jervell and Lange-Nielsen syndrome (N = 19) were enrolled from 22 genetic arrhythmia clinics and 4 registries from 9 countries. KCNE1 variants were evaluated for ECG penetrance (defined as QTc >460 ms on presenting ECG) and genotype-phenotype segregation. Multivariable Cox regression was used to compare the associations between clinical and genetic variables with a composite primary outcome of definite arrhythmic events, including appropriate implantable cardioverter-defibrillator shocks, aborted cardiac arrest, and sudden cardiac death. Results: A total of 32 distinct KCNE1 rare variants were identified in 89 probands and 140 genotype positive family members with presumed LQT5 and an additional 19 Type 2 Jervell and Lange-Nielsen syndrome patients. Among presumed LQT5 patients, the mean QTc on presenting ECG was significantly longer in probands (476.9±38.6 ms) compared with genotype positive family members (441.8±30.9 ms, P <0.001). ECG penetrance for heterozygous genotype positive family members was 20.7% (29/140). A definite arrhythmic event was experienced in 16.9% (15/89) of heterozygous probands in comparison with 1.4% (2/140) of family members (adjusted hazard ratio [HR] 11.6 [95% CI, 2.6–52.2]; P =0.001). Event incidence did not differ significantly for Type 2 Jervell and Lange-Nielsen syndrome patients relative to the overall heterozygous cohort (10.5% [2/19]; HR 1.7 [95% CI, 0.3–10.8], P =0.590). The cumulative prevalence of the 32 KCNE1 variants in the Genome Aggregation Database, which is a human database of exome and genome sequencing data from now over 140 000 individuals, was 238-fold greater than the anticipated prevalence of all LQT5 combined (0.238% vs 0.001%). Conclusions: The present study suggests that putative/confirmed loss-of-function KCNE1 variants predispose to QT prolongation, however, the low ECG penetrance observed suggests they do not manifest clinically in the majority of individuals, aligning with the mild phenotype observed for Type 2 Jervell and Lange-Nielsen syndrome patients.
Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline
Trabulsi, Edouard J. , Rosenkrantz, Andrew B. , Verma, Sadhna , Margolis, Daniel , Froemming, Adam T. , Oto, Aytekin , Milowsky, Matthew I. , Schlemmer, Heinz-Peter, Eiber, Matthias , Padhani, Anwar R. , Jain, Suneil , Pinto, Peter, Keegan, Kirk A., Porter, Christopher R., Jani, Ashesh B. , Kamradt, Jeffrey M., Sholes, Westley, Vargas, H. Alberto, Froemming, Adam, Rumble, R. Bryan , Jadvar, Hossein , Hope, Thomas A. , Pomper, Martin G. , Türkbey, Barış , Purysko, Andrei Saraiva , Morris, Michael J. , Choyke, Peter L. , Oldan, Jorge Daniel , Fanti, Stefano , Coleman, Jonathan , Bauman, Glenn

Mayo Clinic

Journal of Clinical Oncology | January 15, 2020 | Volume: 38 | Issue: 17 | Pages: 1963-1996

10.1200/jco.19.02757 | PMID 31940221 Get It

PURPOSE Provide evidence- and expert-based recommendations for optimal use of imaging in advanced prostate cancer. Due to increases in research and utilization of novel imaging for advanced prostate cancer, this guideline is intended to outline techniques available and provide recommendations on appropriate use of imaging for specified patient subgroups. METHODS An Expert Panel was convened with members from ASCO and the Society of Abdominal Radiology, American College of Radiology, Society of Nuclear Medicine and Molecular Imaging, American Urological Association, American Society for Radiation Oncology, and Society of Urologic Oncology to conduct a systematic review of the literature and develop an evidence-based guideline on the optimal use of imaging for advanced prostate cancer. Representative index cases of various prostate cancer disease states are presented, including suspected high-risk disease, newly diagnosed treatment-naïve metastatic disease, suspected recurrent disease after local treatment, and progressive disease while undergoing systemic treatment. A systematic review of the literature from 2013 to August 2018 identified fully published English-language systematic reviews with or without meta-analyses, reports of rigorously conducted phase III randomized controlled trials that compared ≥ 2 imaging modalities, and noncomparative studies that reported on the efficacy of a single imaging modality. RESULTS A total of 35 studies met inclusion criteria and form the evidence base, including 17 systematic reviews with or without meta-analysis and 18 primary research articles. RECOMMENDATIONS One or more of these imaging modalities should be used for patients with advanced prostate cancer: conventional imaging (defined as computed tomography [CT], bone scan, and/or prostate magnetic resonance imaging [MRI]) and/or next-generation imaging (NGI), positron emission tomography [PET], PET/CT, PET/MRI, or whole-body MRI) according to the clinical scenario.
How has ziconotide impacted non-cancer pain management?
Hagedorn, Jonathan M. , Hagedorn, Jonathan M , Deer, Timothy R.

Mayo Clinic

Expert Opinion on Pharmacotherapy | January 14, 2020 | Volume: 21 | Issue: 5 | Pages: 507-511

10.1080/14656566.2019.1707182 | PMID 31935126 Get It